New Indicator for Response to Therapy in Pediatric Cancers Identified

New indicator for response to therapy in pediatric cancers identified

A study by researchers at the University of Birmingham has identified a new biomarker for response to a specific cancer therapy, treating children with Ewing Sarcoma and other tumor types. The study, which is a Phase I/II treatment arm within the eSMART Trial, was carried out at the Cancer Research UK Clinical Trials Unit (CRCTU), recruited 70 patients, and of those 66 were treated across four countries (the UK, France, the Netherlands and Spain…

Scientists Discover Novel Biomarker Predicting Therapy Response in

In a groundbreaking advancement within pediatric oncology, researchers at the University of Birmingham have uncovered a novel biomarker that could revolutionize the prediction of treatment response in children suffering from Ewing Sarcoma and other challenging solid tumors. This discovery stems from a meticulously conducted Phase I/II clinical trial embedded in the broader AcSé-eSMART study, a […]